Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives Emilio Francesco Giunta, Giuseppe Schepisi, Sara Bleve, Riccardo Serra, Nicole Brighi, Irene Torresan, Elisa Tassinari, Sofia Zanuccoli, Cristian Lolli Discover Oncology, 2026 Neuroendocrine Prostate Cancer (NEPC) is a rare and clinically aggressive subtype of Prostate Cancer (PCa) with its own biological behavior, unfavorable prognosis, and resistance to androgen receptor (AR) directed therapies. De novo NEPC account for less than 1% of PCa cases, whereas a later evolution from castration-resistant PCa (CRPC) to NEPC is more frequent (approximately 15–20% of cases), because of tumor lineage plasticity. The loss of AR signaling, low prostate-specific antigen (PSA) levels, visceral metastases, and significantly reduced survival are the main characteristics of this tumor subtype. In the last decade, the incidence of NEPC has increased, in conjunction with the increasingly frequent use of new AR pathway inhibitors (ARPIs) such as abiraterone, enzalutamide, apalutamide and darolutamide. The increasing incidence of NEPC and especially its disproportionate contribution to mortality in advanced PCa justify the clinical relevance and the growing scientific interest regarding this tumor subtype. By integrating emerging data on NEPC biology, diagnostics, and therapeutics, this review aims to provide a critical and forward-looking description of the current landscape.
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy Milena Urbini, Thomas F. Eleveld, Maurizio Polano, Emanuela Scarpi, Cecilia Menna, Caterina Gianni, Ferdinand W. Janssen, Giuseppe Schepisi, Giorgia Gurioli, Lucia Kucerova, Ad J.M. Gillis, Alessandra Virga, Sara Bleve, Giovanni Rosti, Paola Ulivi, Michal Mego, Leendert H.J. Looijenga, Ugo De Giorgi Journal of Clinical Oncology, 2026 PURPOSE High-dose chemotherapy (HDCT) is one of the salvage therapy options for patients with relapsed/refractory germ cell tumors (rGCT) after failure of first-line chemotherapy. We aimed to identify circulating biomarkers predicting clinical response and outcome of HDCT. METHODS Baseline and on-treatment plasma samples from 69 HDCT-treated and 26 conventional-dose chemotherapy (CDCT)-treated GCT patients were analyzed by shallow whole-genome sequencing. Tumor fraction (TF) and copy-number alterations (CNAs) were determined using ichorCNA, compared with miR-371a-3p levels, and correlated with progression-free survival (PFS) and overall survival (OS). CNA profiles from external tissue GCT cohorts were used for validation. RESULTS TF was detectable in 75.4% of baseline plasma of HDCT patients. High TF was strongly associated with worse OS in HDCT-treated nonseminomas ( P = .021). This was confirmed in the CDCT cohort ( P = .039), where shorter median OS was observed in high-TF patients compared with the HDCT cohort. Conversely, miR-371a-3p levels were not prognostic. Plasma CNA profiling confirmed the high frequency of chromosome 3p gain in rGCT cases and revealed other alterations linked to poor HDCT outcomes, including 9q and 11q gains and 6q loss. These CNAs were enriched in a cluster predominantly composed of GCT with extra-embryonic histology (yolk sac and choriocarcinoma). Unsupervised clustering of CNA profile of plasma identified 13 patients in this high-risk cluster, who had significantly worse PFS and OS compared with other rGCT cases. CONCLUSION Analysis of cell free DNA provides valuable prognostic information in rGCTs. High baseline TF and specific CNA patterns linked to extra-embryonic histology identify patients at higher risk of poor outcomes. HDCT seems to be more effective than CDCT in high-TF patients. These minimally invasive biomarkers could refine risk stratification and guide selection of salvage therapies in rGCTs.
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy Sara Bleve, Francesco Ravera, Silvia Rodrigues, Filippo Pederzoli, Hubert Pakula, Nicole Brighi, Emilio Francesco Giunta, Giuseppe Schepisi, Alessandra Virga, Giorgia Gurioli, Salvatore Luca Burgio, Giuseppe Nicolo’ Fanelli, Lisa M. Butler, David M. Nanus, Johannes V. Swinnen, Pier Vitale Nuzzo, Cristian Lolli, Ugo De Giorgi, Massimo Loda Prostate Cancer and Prostatic Diseases, 2026 Background Reprogrammed lipid metabolism with massive upregulation of tumor cell-autonomous synthesis of saturated fatty acids is a hallmark of prostate cancer (PCa) and is driven in part by aberrations in androgen receptor (AR) signaling. While lipid alterations are well described in primary PCa, the extent to which the circulating lipidome reflects tumor-associated metabolic changes in metastatic disease, and its role in therapy response, remains to be determined. This study aims to assess whether plasma lipid profiling captures tumor metabolic rewiring, and whether this reflects response to AR-targeting therapy, in metastatic castration-resistant PCa (mCRPC). Methods Quantitative plasma lipidomics was performed on plasma samples collected from patients with mCRPC ( n = 50) and cancer-free subjects (C-FS, n = 14). Samples from patients with mCRPC were collected longitudinally at the time of progression on androgen deprivation therapy prior to initiation of first-line enzalutamide (Enza), after the start of treatment with Enza, before progression on Enza. Results Compared to C-FS, patients with mCRPC showed distinct lipidomic signatures, characterized by increased levels of monounsaturated lipids and altered composition of the phospholipid and sphingolipid pool, mimicking the aberrations known to occur in primary PCa tissue. Enza treatment markedly reduced total lipid levels, decreased major phospholipid classes and ceramides, while increasing sphingomyelins. Notably, quantitative differences in specific sphingolipid species occurring after Enza treatment correlated with survival outcomes. Conclusions Plasma lipidomics reflects key metabolic features of PCa and is profoundly impacted by AR inhibition, with prognostic relevance in patients with mCRPC. These findings support its potential as a non-invasive tool for monitoring disease activity and treatment response, and lay the groundwork for lipid-based biomarkers in mCRPC, while indicating that the lipidomic alterations observed may help inform ongoing and forthcoming research on metabolic targeting.
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience Giuseppina Bruno, Maria Iole Natalicchio, Marianna Garofoli, Cristian Lolli, Aldo Rosano, Piergiorgio Di Tullio, Guido Giordano, Alice Mancino, Mariachiara Masucci, Vincenzo Emanuele Chiuri, Lucia Fratino, Elisa Zanardi, Giuseppe Schepisi, Luca Galli, Francesco Massari, Matteo Santoni, Nicole Brighi, Elisabetta Cornacchia, Pasquale Rescigno, Giuseppe Fornarini, Francesca Sanguedolce, Daniele Santini, Giuseppe Procopio, Orazio Caffo, Ugo De Giorgi, Matteo Landriscina, Vincenza Conteduca European Urology Oncology, 2025 BACKGROUND AND OBJECTIVE: The prognostic impact of lung metastases (LuMs) in metastatic castration-resistant prostate cancer (mCRPC) remains poorly defined. Our aim was to evaluate the clinical and molecular characteristics of patients with mCRPC with LuMs and their outcomes. METHODS: This retrospective multicenter study included 930 patients with mCRPC across 13 centers in Italy. The primary endpoint was the impact of LuMs on overall survival (OS), progression-free survival (PFS), and prostate-specific antigen (PSA) response. As a secondary endpoint, next-generation sequencing for a subgroup with LuMs was used to identify molecular characteristics that might be useful in guiding personalized therapy. KEY FINDINGS AND LIMITATIONS: Among mCRPC patients treated with an androgen receptor signaling inhibitor, we observed no significant differences in median OS or PFS and PSA response between the LuMs group and the group with bone ± lymph node metastases. Multivariable analyses revealed that only Eastern Cooperative Oncology Group performance status, PSA level, prior docetaxel treatment, and number of metastatic lesions were significant independent factors for both OS and PFS. Comparison of the groups with LuMs only versus liver metastases revealed a significant association between LuMs and a longer OS (15 vs 10 mo; p = 0.002) and PFS (9 vs 5 mo; p = 0.002). The proportion of patients with a ≥50% PSA decline was higher in the LuMs group (odds ratio 3.57, 95% confidence interval 1.37-9.45; p = 0.004). Molecular profile results showed that TP53 mutations accounted for a lower proportion of the pathogenic variants in LuMs than in liver metastases (15% vs 89%). Limitations include the retrospective design and clinical heterogeneity of the population, in addition to unavailability of metastatic biopsies for more in-depth analyses. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings suggest that patients with LuMs in mCRPC exhibit clinical and molecular features more similar to those with bone ± lymph nodal metastases than to patients with liver metastases. Further prospective studies are warranted.
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care Vincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, Giuseppina Bruno, Cristian Lolli, Giuseppe Schepisi, Aldo Rosano, Guido Giordano, Marianna Garofoli, Vincenzo Emanuele Chiuri, Lucia Fratino, Elisa Zanardi, Luca Galli, Francesco Massari, Ugo Falagario, Pasquale Rescigno, Giuseppe Fornarini, Francesca Sanguedolce, Daniele Santini, Giuseppe Procopio, Orazio Caffo, Giuseppe Carrieri, Matteo Landriscina, Ugo De Giorgi Prostate Cancer and Prostatic Diseases, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer Vincenza Conteduca, Emanuela Scarpi, Alice Rossi, Fabio Ferroni, Giorgia Gurioli, Sara Bleve, Caterina Gianni, Giuseppe Schepisi, Nicole Brighi, Cristian Lolli, Maria Concetta Cursano, Alessandra Virga, Chiara Casadei, Amelia Altavilla, Alberto Farolfi, Paola Ulivi, Domenico Barone, Federica Matteucci, Ugo De Giorgi Oncologist, 2025 Background Circulating tumor DNA (ctDNA) acts as an early biomarker of the efficacy of androgen receptor signaling inhibitor (ARSI) therapy. In this study, we aimed to reveal if ctDNA can supplement imaging to better predict metastasis burden and radiographic progression disease (PD) in metastatic castration-resistant prostate cancer (mCRPC). Methods Targeted next-generation sequencing was performed to assess ctDNA fraction. Radiographic evidence was documented by conventional imaging according to Prostate Cancer Working Group 3 criteria. Results We prospectively collected plasma samples from 112 mCRPC with bone (n = 77), lymph nodal (n = 31), and visceral (n = 4) metastases. Only bone metastatic patterns were significantly associated with median ctDNA at baseline, during treatment and at PD (P <.0001). At first radiographic restaging, 24 (31.2%) men with a progressive worsening of bone disease had early ctDNA rise with a % ctDNA variation of 150.6% (interquartile range [IQR] = 104.9-210.7] compared with 11.1% (IQR = 0-36.6), P <.0001, in men with no change in bone disease. Univariate analysis showed that early ctDNA rise was significantly associated with progression free/overall survival (PFS/OS). In multivariable analysis including ctDNA change from baseline to 3-month treatment, variation of bone metastatic patterns (from oligometastatic to polymetastatic and/or to widespread disease), presence of visceral metastasis, age, PSA, performance status and prior docetaxel therapy, the transition from low- to high-ctDNA within 3 months of starting ARSI therapy was a significant predictor of OS (HR = 2.50, 90% CI, 1.06-5.88, P =.035) and persistent high level of ctDNA was a predictor of PFS (HR = 2.53, 95% CI, 1.10-5.81, P =.028). Metastatic involvement demonstrated that the transition from bone polymetastatic to widespread disease and the presence of visceral metastases were both associated with worse OS (HR = 2.43, 95% CI, 1.10-5.35, P =.028, and HR = 3.40, 95% CI, 1.50-7.66, P =.003, respectively). Prior therapy with docetaxel represented an independent predictor of both PFS and OS (HR = 2.47, 95% CI, 1.40-4.35, P =.002, and HR = 1.78, 95% CI, 1.00-3.15, P =.049, respectively). Conclusions Early ctDNA variation might reflect changes in metastatic burden and, likely, in bone metastatic patterns on ARSI therapy allowing to track pattern of disease progression and to predict outcome.
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial G. Schepisi, M. Urbini, C. Casadei, V. Gallà, S. Rossetti, U. Basso, C. Lolli, G. Gurioli, E. Petracci, S. Cecere, J. Ventriglia, V. Zampiga, A. Miserocchi, I. Cangini, I. De Santis, M. Di Napoli, C. Menna, G. Mambelli, S. Pignata, U. De Giorgi ESMO Open, 2025 BACKGROUND: Therapeutic options for patients with advanced germ-cell tumors (GCTs) after multiple relapses or resistant disease are limited. Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. PATIENTS AND METHODS: In this proof-of principle open-label, single-arm, phase II trial of olaparib 300 mg twice daily in patients with relapsed/refractory metastatic germ-cell cancer [IGG-02 study (NCT02533765)], patient eligibility included failure after high-dose chemotherapy or after at least two different cisplatin-based regimens. RESULTS: Between September 2015 and February 2019, 18 patients, with a median age of 39 years (range 22-61 years) were enrolled. Severe adverse events (AEs) were observed in seven patients. There were no partial responses, five cases (27.8%) with stable disease (SD) lasting 3, 4, 4, 7 and 43 months, and 13 (72.2%) progressive disease. A germline DNA repair profile panel showed only a BRCA1-mutated case associated with an SD lasting for 4 months. The long-lasting patient on olaparib (43 months) experienced a myelodisplastic syndrome (MDS) associated with the onset of a pathogenic mutation affecting PPM1D. CONCLUSIONS: Olaparib as a single agent demonstrated no activity in heavily pretreated GCT patients. Future studies with PARP inhibitors should be planned in less-pretreated GCT patients based on molecular analysis to support better patient selection.
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes Nicole Brighi, Giuseppe Schepisi, Vincenza Conteduca, Emanuela Scarpi, Paola Caroli, Federica Matteucci, Cristian Lolli Oncotargets and Therapy, 2025 Purpose There is an urgent need of biomarkers to personalize metastatic castration-resistant prostate cancer (mCRPC) treatment. A new prognostic model described by our group combines molecular characteristics (ptDNA levels), metabolic features from PET-scans (metabolic tumor volume), clinical parameters (visceral metastases), and lab tests (lactate-dehydrogenase levels) in abiraterone or enzalutamide-treated patients. This study aims to validate the score on mCRPC patients undergoing taxane treatment. Patients and Methods Twenty-eight patients affected by mCRPC, pre-treated with abiraterone or enzalutamide, candidate for taxane-based treatments, have been prospectively evaluated. All patients underwent a basal PET/CT scan with F-choline and blood samples. The prognostic model previously described was applied to this population; based on the partial results of the parameters, we assigned the patients into three risk groups. Results In the 28 patients evaluated, we observed a different median OS among the three risk groups (risk group I, 18.1 months [95% CI: 15.2–33.1 months]; risk group II, 12.7 months [4.9–18.6 months]; and risk group III, 10.1 months [3.4–15.4 months]; p = 0.012). Statistically significant differences were also observed for PFS. Conclusion The prognostic score has confirmed to be a good prognostic tool also in a more advanced cohort of patients treated with taxanes. This tool may represent a valid method to refine prognostication and treatment selection in a cohort of patients where biomarkers are scarce.
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients Emilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, Amelia Altavilla, Virginia Rossetti, Irene Marini, Monica Celli, Chiara Casadei, Cristian Lolli, Giuseppe Schepisi, Sara Bleve, Nicole Brighi, Maria Concetta Cursano, Giovanni Paganelli, Federica Matteucci, Ugo De Giorgi European Journal of Nuclear Medicine and Molecular Imaging, 2024 PURPOSE: Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy. METHODS: Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method. RESULTS: 69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones. CONCLUSIONS: Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions.
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study Chiara Casadei, Emanuela Scarpi, Vincenza Conteduca, Giorgia Gurioli, Maria Concetta Cursano, et al. European Urology Open Science, 2024 The prevalence of pathogenic germline mutations in DNA damage repair (gDDR) genes in the Italian population is unknown. In this prospective multicenter cohort study, we evaluated the prevalence of gDDR alterations in the Italian population affected by metastatic prostate cancer (mPCa) and analyzed the impact on response to therapy, survival, and time to castration resistance. In an observational prospective trial, 300 consecutive Italian mPCa patients, enrolled in the Meet-Uro-10 trial from three academic Italian centers, were recruited between 2017 and 2019 and were screened for gDDR mutations in 107 genes. The primary endpoint was to assess the prevalence of gDDR mutations in the Italian population of patients with mPCa. The secondary endpoints included the association of gDDR subgroups with metastatic onset, Gleason score, and time to castration resistance. We identified 297 valuable patients. Forty-six patients had a pathogenic/likely pathogenic variant (15.5%, 95% confidence interval: 11.4–19.6): the more frequent was gBRCA2 found in nine cases (3%), followed by gATM in five cases (1.7%). In patients without mutations, longer median overall survival was observed with the sequence docetaxel-androgen receptor signaling inhibitor (ARSI) than with the sequence ARSI-docetaxel (87.9 vs 42 mo, p = 0.0001). In a univariate analysis, the median time to castration resistance in gDDR mutated patients was 19.8 mo, versus 23.7 mo in no mutated patients (p = 0.024). There were no associations of gDDR subgroups with metastatic onset and Gleason score ≥8. In our cohort, variants of unknown significance in gDDR genes were found in 80 patients and might have a prognostic relevance. The study reported the prevalence of gDDR in the Italian population. The presence of gBRCA2 mutations correlates with a shorter time to the onset of castration resistance disease. The prevalence of gBRCA2 in the Italian population is 3%, which is similar to that in the Spanish population, identifying similarities between people of the Western Mediterranean area.
Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza) Sara Bleve, Francesco Ravera, Silvia Rodrigues, Mohamed Omar, Emilio Francesco Giunta, Filippo Pederzoli, Hubert Pakula, Amelia Altavilla, Nicole Brighi, Giorgia Gurioli, Maria Concetta Cursano, Chiara Casadei, Cristian Lolli, Giuseppe Schepisi, David M. Nanus, Pier Vitale Nuzzo, Ugo De Giorgi, Massimo Loda Journal of Clinical Oncology, 2024
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer Sara Bleve, Maria Concetta Cursano, Chiara Casadei, Giuseppe Schepisi, Cecilia Menna, Milena Urbini, Caterina Gianni, Silvia De Padova, Alessia Filograna, Valentina Gallà, Giovanni Rosti, Domenico Barone, Michal Chovanec, Michal Mego, Ugo De Giorgi Frontiers in Oncology, 2022
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients Vincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, Nicole Brighi, Fabio Ferroni, Alice Rossi, Alessandro Romanel, Giorgia Gurioli, Sara Bleve, Caterina Gianni, Giuseppe Schepisi, Cristian Lolli, Pietro Cortesi, Federica Matteucci, Domenico Barone, Giovanni Paganelli, Francesca Demichelis, Himisha Beltran, Gerhardt Attard, Ugo De Giorgi International Journal of Cancer, 2022
Review vitamin d deficiency in testicular cancer survivors: A systematic review Giuseppe Schepisi, Caterina Gianni, Sara Bleve, Silvia De Padova, Cecilia Menna, Cristian Lolli, Alessia Filograna, Vincenza Conteduca, Milena Urbini, Valentina Gallà, Chiara Casadei, Giovanni Rosti, Ugo De Giorgi International Journal of Molecular Sciences, 2021
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors Giuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, Giorgia Gurioli, Lorena Rossi, Valentina Gallà, Maria Concetta Cursano, Nicole Brighi, Cristian Lolli, Cecilia Menna, Alberto Farolfi, Salvatore Luca Burgio, Amelia Altavilla, Giovanni Martinelli, Ugo De Giorgi Frontiers in Oncology, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer Vincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, Alessandro Romanel, Giorgia Gurioli, Anuradha Jayaram, Cristian Lolli, Delila Gasi Tandefelt, Giuseppe Schepisi, Chiara Casadei, Anna Wingate, Federica Matteucci, Giovanni Paganelli, Enrique Gonzalez-Billalabeitia, Francesca Demichelis, Ugo De Giorgi, Gerhardt Attard British Journal of Cancer, 2020
Plasma androgen receptor in prostate cancer Vincenza Conteduca, Giorgia Gurioli, Nicole Brighi, Cristian Lolli, Giuseppe Schepisi, Chiara Casadei, Salvatore Luca Burgio, Stefania Gargiulo, Giorgia Ravaglia, Lorena Rossi, Amelia Altavilla, Alberto Farolfi, Cecilia Menna, Sarah Pia Colangione, Mario Pulvirenti, Antonino Romeo, Ugo De Giorgi Cancers, 2019
CAR-T cell therapy: A potential new strategy against prostate cancer Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli, Ugo De Giorgi Journal for Immunotherapy of Cancer, 2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer Vincenza Conteduca, Elena Castro, Daniel Wetterskog, Emanuela Scarpi, Anuradha Jayaram, Nuria Romero-Laorden, David Olmos, Giorgia Gurioli, Cristian Lolli, Maria Isabel Sáez, Javier Puente, Giuseppe Schepisi, Samanta Salvi, Anna Wingate, Ana Medina, Rosa Querol-Niñerola, Mercedes Marin-Aguilera, Jose Angel Arranz, Giuseppe Fornarini, Umberto Basso, Begoña Mellado, Enrique Gonzalez-Billalabeitia, Gerhardt Attard, Ugo De Giorgi European Journal of Cancer, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C. Villa-Guzmán, Susana Hernando, Alejo Rodriguez-Vida, Aránzazu González-del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi European Urology, 2019
Psychosocial issues in long-term survivors of testicular cancer Giuseppe Schepisi, Silvia De Padova, Delia De Lisi, Chiara Casadei, Elena Meggiolaro, Federica Ruffilli, Giovanni Rosti, Cristian Lolli, Giorgia Ravaglia, Vincenza Conteduca, Alberto Farolfi, Luigi Grassi, Ugo De Giorgi Frontiers in Endocrinology, 2019
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors Giuseppe Schepisi, Nicole Brighi, Maria Concetta Cursano, Giorgia Gurioli, Giorgia Ravaglia, Amelia Altavilla, Salvatore Luca Burgio, Sara Testoni, Cecilia Menna, Alberto Farolfi, Chiara Casadei, Giuseppe Tonini, Daniele Santini, Ugo De Giorgi Journal of Oncology, 2019
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support Silvia De Padova, Chiara Casadei, Alejandra Berardi, Tatiana Bertelli, Alessia Filograna, Maria Concetta Cursano, Cecilia Menna, Salvatore Luca Burgio, Amelia Altavilla, Giuseppe Schepisi, Sabrina Prati, Sandra Montalti, Michal Chovanec, Giuseppe Luigi Banna, Luigi Grassi, Michal Mego, Ugo De Giorgi Frontiers in Endocrinology, 2019
Immunotherapy for prostate cancer: Where we are headed Giuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, Filippo Martignano, Delia De Lisi, Giorgia Ravaglia, Lorena Rossi, Cecilia Menna, Salvatore Roberto Bellia, Domenico Barone, Roberta Gunelli, Ugo De Giorgi International Journal of Molecular Sciences, 2017
Vitamin D status among long-term survivors of testicular cancer Giuseppe Schepisi, Silvia De Padova, Emanuela Scarpi, Cristian Lolli, Giorgia Gurioli, Cecilia Menna, Salvatore L. Burgio, Lorena Rossi, Valentina Gallà, Valentina Casadio, Samanta Salvi, Vincenza Conteduca, Ugo De Giorgi Oncotarget, 2017
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review Francesco Jacopo Romano, Sabrina Rossetti, Vincenza Conteduca, Giuseppe Schepisi, Carla Cavaliere, Rossella Di Franco, Elvira La Mantia, Luigi Castaldo, Flavia Nocerino, Gianluca Ametrano, Francesca Cappuccio, Gabriella Malzone, Micaela Montanari, Daniela Vanacore, Vincenzo Quagliariello, Raffaele Piscitelli, Maria Filomena Pepe, Massimiliano Berretta, Carmine D'Aniello, Sisto Perdonà, Paolo Muto, Gerardo Botti, Gennaro Ciliberto, Bianca Maria Veneziani, Francesco De Falco, Piera Maiolino, Michele Caraglia, Maurizio Montella, Ugo De Giorgi, Gaetano Facchini Oncotarget, 2016
Taxane-related nail toxicity Giuseppe Schepisi, Vincenza Conteduca, Cristian Lolli, Matelda Medri, Ugo De Giorgi Lancet Oncology, 2015
